Charles River Laboratories International, Inc. (CRL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CRL Revenue Growth
Revenue Breakdown (FY 2025)
CRL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CRL Revenue Analysis (2014–2025)
As of May 6, 2026, Charles River Laboratories International, Inc. (CRL) generated trailing twelve-month (TTM) revenue of $4.02 billion, reflecting slight decline in growth of -0.8% year-over-year. The most recent quarter (Q4 2025) recorded $994.2 million in revenue, down 1.1% sequentially.
Looking at the longer-term picture, CRL's 5-year compound annual growth rate (CAGR) stands at +6.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $4.13 billion in 2023.
Revenue diversification analysis shows CRL's business is primarily driven by Discovery and Safety Assessment (60%), Research Models and Services (21%), and Manufacturing Support (19%). With over half of revenue concentrated in Discovery and Safety Assessment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IQV (+7.3% YoY), MEDP (+24.2% YoY), and ICLR (-2.5% YoY), CRL has underperformed the peer group in terms of revenue growth. Compare CRL vs IQV →
CRL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRLCurrent | $4.0B | -0.8% | +6.5% | 12.6% | |
 IQV | $16.3B | +7.3% | +7.5% | 14.0% | |
 MEDP | $2.5B | +24.2% | +22.3% | 21.1% | |
 ICLR | $8.3B | -2.5% | +24.2% | 13.3% | |
 PRA | $1.1B | -3.9% | +4.4% | 6.6% | |
 LBRT | $4.0B | -4.0% | +32.9% | 2.0% |
CRL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.02B | -0.9% | $1.23B | 30.5% | $507.8M | 12.6% |
| 2024 | $4.05B | -1.9% | $1.33B | 32.9% | $227.3M | 5.6% |
| 2023 | $4.13B | +3.9% | $1.50B | 36.4% | $617.3M | 14.9% |
| 2022 | $3.98B | +12.3% | $1.46B | 36.8% | $651.0M | 16.4% |
| 2021 | $3.54B | +21.1% | $1.33B | 37.7% | $589.9M | 16.7% |
| 2020 | $2.92B | +11.5% | $1.07B | 36.7% | $432.7M | 14.8% |
| 2019 | $2.62B | +15.7% | $958.3M | 36.6% | $351.2M | 13.4% |
| 2018 | $2.27B | +22.0% | $840.1M | 37.1% | $331.4M | 14.6% |
| 2017 | $1.86B | +10.5% | $700.9M | 37.7% | $288.3M | 15.5% |
| 2016 | $1.68B | +23.3% | $644.0M | 38.3% | $237.6M | 14.1% |
See CRL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRL — Frequently Asked Questions
Quick answers to the most common questions about buying CRL stock.
Is CRL's revenue growth accelerating or slowing?
CRL revenue growth slowed to -0.8%, below the 5-year CAGR of +6.5%. TTM revenue is $4.0B. The deceleration marks a shift from historical growth rates.
What is CRL's long-term revenue growth rate?
Charles River Laboratories International, Inc.'s 5-year revenue CAGR of +6.5% reflects the variable expansion pattern. Current YoY growth of -0.8% is near this long-term average.
How is CRL's revenue distributed by segment?
CRL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.